1 active not recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Nanopass Technologies Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function Lymphatic clearance measurement - Lymphedema, Secondary Lymphedema | Phase 1 | Completed | Nicole Lindenblatt | 10 | 2020-05-22 | 2020-07-14 |
Fallopian Tube Neoplasms (1) · Lymphedema (1) · Ovarian Neoplasms (1)
Biopsy (1) · Blood Component Removal (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · pembrolizumab (1)
Switzerland (1) · United States (1)
Matthew S. Block, MD, PhD (1) · Nicole Lindenblatt, M.D, PhD (1)
2019 (1), R01CA276313 (1)